Duke Cancer Institute, Duke University Medical Center, Durham, NC, 27710, USA.
Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population.
Written by:
Bitting RL, Armstrong AJ, George DJ. Are you the author?
Reference: Clin Med Insights Oncol. 2011;5:325-32.
doi: 10.4137/CMO.S5977
PubMed Abstract
PMID: 22084621
UroToday.com Prostate Cancer Section
